{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:27:44Z","timestamp":1767983264438,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["A2018-032"],"award-info":[{"award-number":["A2018-032"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["A2018-032"],"award-info":[{"award-number":["A2018-032"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07145-3","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:51:24Z","timestamp":1760705484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4644-9404","authenticated-orcid":false,"given":"Chie","family":"Kudo-Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Tsugaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Amanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"3","key":"7145_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"7145_CR2","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012\u201320.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7145_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","volume":"27","author":"N Boku","year":"2024","unstructured":"Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, et al. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial. Gastric Cancer. 2024;27(6):1287\u2013301.","journal-title":"Gastric Cancer"},{"issue":"14","key":"7145_CR4","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.jmb.2018.05.030","volume":"430","author":"N Borcherding","year":"2018","unstructured":"Borcherding N, Kolb R, Gullicksrud J, Vikas P, Zhu Y, Zhang W. Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. J Mol Biol. 2018;430(14):2014\u201329.","journal-title":"J Mol Biol"},{"key":"7145_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3389\/fonc.2020.01027","volume":"10","author":"O Lapuente-Santana","year":"2020","unstructured":"Lapuente-Santana O, Eduati F. Toward systems biomarkers of response to immune checkpoint blockers. Front Oncol. 2020;10:1027.","journal-title":"Front Oncol"},{"issue":"11","key":"7145_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010174","volume":"12","author":"H Shoji","year":"2024","unstructured":"Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, et al. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). J Immunother Cancer. 2024;12(11):e010174.","journal-title":"J Immunother Cancer"},{"key":"7145_CR7","doi-asserted-by":"publisher","first-page":"1192506","DOI":"10.3389\/fimmu.2023.1192506","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Xuan S, Dong P, Xiang Z, Gao C, Li M, et al. Immunotherapy of hepatocellular carcinoma: recent progress and new strategy. Front Immunol. 2023;14:1192506.","journal-title":"Front Immunol"},{"issue":"11","key":"7145_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"7145_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/0008-5472.CAN-19-2235","volume":"80","author":"C Kudo-Saito","year":"2020","unstructured":"Kudo-Saito C, Miyamoto T, Imazeki H, Shoji H, Aoki K, Boku N. IL33 is a key driver of treatment resistance of cancer. Cancer Res. 2020;80(10):1981\u201390.","journal-title":"Cancer Res"},{"key":"7145_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120214","volume":"289","author":"MZ Jovanovic","year":"2022","unstructured":"Jovanovic MZ, Geller DA, Gajovic NM, Jurisevic MM, Arsenijevic NN, Jovanovic MM, et al. Dual blockage of PD-L\/PD-1 and IL33\/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. Life Sci. 2022;289:120214.","journal-title":"Life Sci"},{"issue":"9","key":"7145_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009236","volume":"12","author":"Y Nan","year":"2024","unstructured":"Nan Y, Bai Y, Hu X, Zhou K, Wu T, Zhu A, et al. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. J Immunother Cancer. 2024;12(9):e009236.","journal-title":"J Immunother Cancer"},{"key":"7145_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3389\/fimmu.2020.01389","volume":"11","author":"MF Eissmann","year":"2020","unstructured":"Eissmann MF, Buchert M, Ernst M. IL33 and mast cells-the key regulators of immune responses in gastrointestinal cancers? Front Immunol. 2020;11:1389.","journal-title":"Front Immunol"},{"issue":"10","key":"7145_CR13","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3390\/cells8101290","volume":"8","author":"CJ Kuo","year":"2019","unstructured":"Kuo CJ, Chen CY, Lo HR, Feng CL, Wu HY, Huang MZ, et al. Helicobacter pylori induces IL-33 production and recruits ST-2 to lipid rafts to exacerbate inflammation. Cells. 2019;8(10):1290.","journal-title":"Cells"},{"issue":"5","key":"7145_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3892\/mmr.2021.12000","volume":"23","author":"N Huang","year":"2021","unstructured":"Huang N, Cui X, Li W, Zhang C, Liu L, Li J. IL-33\/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway. Mol Med Rep. 2021;23(5):361.","journal-title":"Mol Med Rep"},{"issue":"5","key":"7145_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s10620-014-3463-1","volume":"60","author":"XX Yu","year":"2015","unstructured":"Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1\/2 pathway. Dig Dis Sci. 2015;60(5):1265\u201372.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"7145_CR16","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3892\/or.2015.3898","volume":"33","author":"XL Ye","year":"2015","unstructured":"Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN, Shao JP, et al. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33(6):2746\u201352.","journal-title":"Oncol Rep"},{"issue":"7","key":"7145_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41388-022-02575-5","volume":"42","author":"JW Kwon","year":"2023","unstructured":"Kwon JW, Seok SH, Kim S, An HW, Choudhury AD, Woo SH, et al. A synergistic partnership between IL-33\/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis. Oncogene. 2023;42(7):501\u201315.","journal-title":"Oncogene"},{"issue":"6","key":"7145_CR18","doi-asserted-by":"publisher","first-page":"2077-91e8","DOI":"10.1053\/j.gastro.2020.08.051","volume":"159","author":"AR Meyer","year":"2020","unstructured":"Meyer AR, Engevik AC, Madorsky T, Belmont E, Stier MT, Norlander AE, et al. Group 2 innate lymphoid cells coordinate damage response in the stomach. Gastroenterology. 2020;159(6):2077-91e8.","journal-title":"Gastroenterology"},{"issue":"2","key":"7145_CR19","doi-asserted-by":"publisher","first-page":"637-52e4","DOI":"10.1053\/j.gastro.2021.04.075","volume":"161","author":"JT Busada","year":"2021","unstructured":"Busada JT, Peterson KN, Khadka S, Xu X, Oakley RH, Cook DN, et al. Glucocorticoids and androgens protect from gastric metaplasia by suppressing group 2 innate lymphoid cell activation. Gastroenterology. 2021;161(2):637-52e4.","journal-title":"Gastroenterology"},{"issue":"1","key":"7145_CR20","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1038\/s41467-019-10676-1","volume":"10","author":"MF Eissmann","year":"2019","unstructured":"Eissmann MF, Dijkstra C, Jarnicki A, Phesse T, Brunnberg J, Poh AR, et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nat Commun. 2019;10(1):2735.","journal-title":"Nat Commun"},{"key":"7145_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jare.2023.04.013","volume":"57","author":"Y Lv","year":"2024","unstructured":"Lv Y, Tian W, Teng Y, Wang P, Zhao Y, Li Z, et al. Tumor-infiltrating mast cells stimulate ICOS(+) regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression. J Adv Res. 2024;57:149\u201362.","journal-title":"J Adv Res"},{"issue":"12","key":"7145_CR22","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1007\/s10620-011-1760-5","volume":"56","author":"P Sun","year":"2011","unstructured":"Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011;56(12):3596\u2013601.","journal-title":"Dig Dis Sci"},{"issue":"21","key":"7145_CR23","doi-asserted-by":"publisher","first-page":"35116","DOI":"10.18632\/oncotarget.16627","volume":"8","author":"W Hu","year":"2017","unstructured":"Hu W, Wu C, Li X, Zheng Z, Xie Q, Deng X, et al. Serum IL-33 level is a predictor of progression-free survival after chemotherapy. Oncotarget. 2017;8(21):35116\u201323.","journal-title":"Oncotarget"},{"issue":"7","key":"7145_CR24","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/s41388-019-1078-x","volume":"39","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Wu X, Wang X, Yu Z, Pan T, Li Z, et al. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-alpha\/IL-33\/ST2L signaling promotes gastric cancer metastasis. Oncogene. 2020;39(7):1414\u201328.","journal-title":"Oncogene"},{"issue":"3","key":"7145_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12253-016-0167-1","volume":"23","author":"W Hu","year":"2017","unstructured":"Hu W, Li X, Li Q, Tan Y, Xu B, Xie Q, et al. Interleukin-33 expression does not correlate with survival of gastric cancer patients. Pathol Oncol Res. 2017;23(3):615\u20139.","journal-title":"Pathol Oncol Res"},{"key":"7145_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"key":"7145_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/9780470258019","volume-title":"Applied survival analysis: regression modeling of time-to-event data","author":"DW Hosmer","year":"2008","unstructured":"Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event data. 2nd ed. Hoboken: Wiley-Interscience; 2008. p. 392.","edition":"2"},{"issue":"1","key":"7145_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12619","volume":"281","author":"C Cayrol","year":"2018","unstructured":"Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281(1):154\u201368.","journal-title":"Immunol Rev"},{"issue":"5","key":"7145_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9(5):e96801.","journal-title":"PLoS ONE"},{"key":"7145_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3389\/fonc.2019.01353","volume":"9","author":"Z Luo","year":"2019","unstructured":"Luo Z, Rong Z, Huang C. Surgery strategies for gastric cancer with liver metastasis. Front Oncol. 2019;9:1353.","journal-title":"Front Oncol"},{"issue":"6","key":"7145_CR31","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers15061777","volume":"15","author":"I Manzanedo","year":"2023","unstructured":"Manzanedo I, Pereira F, Perez-Viejo E, Serrano A. Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment. Cancers (Basel). 2023;15(6):1777.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"7145_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109823","volume":"41","author":"JR Kovalski","year":"2022","unstructured":"Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J. 2022;41(8):e109823.","journal-title":"EMBO J"},{"key":"7145_CR33","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","volume":"9","author":"C Afferni","year":"2018","unstructured":"Afferni C, Buccione C, Andreone S, Galdiero MR, Varricchi G, Marone G, et al. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Front Immunol. 2018;9:2601.","journal-title":"Front Immunol"},{"issue":"1","key":"7145_CR34","doi-asserted-by":"publisher","first-page":"300060521105315","DOI":"10.1177\/03000605211053156","volume":"50","author":"J Jin","year":"2022","unstructured":"Jin J, Sunusi S, Lu H. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. J Int Med Res. 2022;50(1):3000605211053156.","journal-title":"J Int Med Res"},{"issue":"3","key":"7145_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41590-022-01127-z","volume":"23","author":"N Jacquelot","year":"2022","unstructured":"Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol. 2022;23(3):371\u20139.","journal-title":"Nat Immunol"},{"issue":"1","key":"7145_CR36","doi-asserted-by":"publisher","first-page":"2347025","DOI":"10.1080\/19490976.2024.2347025","volume":"16","author":"R Peng","year":"2024","unstructured":"Peng R, Xu C, Zhang L, Liu X, Peng D, Chen X, et al. M2 macrophages participate in ILC2 activation induced by Helicobacter pylori infection. Gut Microbes. 2024;16(1):2347025.","journal-title":"Gut Microbes"},{"key":"7145_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/923135","volume":"2014","author":"Q Bie","year":"2014","unstructured":"Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu Y, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014;2014:923135.","journal-title":"J Immunol Res"},{"issue":"1","key":"7145_CR38","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1038\/s41467-023-42215-4","volume":"14","author":"RN O'Keefe","year":"2023","unstructured":"O\u2019Keefe RN, Carli ALE, Baloyan D, Chisanga D, Shi W, Afshar-Sterle S, et al. A tuft cell - ILC2 signaling circuit provides therapeutic targets to inhibit gastric metaplasia and tumor development. Nat Commun. 2023;14(1):6872.","journal-title":"Nat Commun"},{"key":"7145_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/OTT.S389120","volume":"16","author":"A Chatterjee","year":"2023","unstructured":"Chatterjee A, Azevedo-Martins JM, Stachler MD. Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights. Onco Targets Ther. 2023;16:675\u201387.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"7145_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00432-022-04408-0","volume":"149","author":"C Rocken","year":"2023","unstructured":"Rocken C. Predictive biomarkers in gastric cancer. J Cancer Res Clin Oncol. 2023;149(1):467\u201381.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07145-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:51:25Z","timestamp":1760705485000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07145-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7145"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07145-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The WJOG10417GTR study (UMIN000032686) was conducted in ten hospitals according to the protocol approved by the IRB of each participating hospital, including the National Cancer Center (No. 2017\u2013473). Informed consent was obtained from all subjects. All activities were conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.K.-S. received honoraria from Ono Pharmaceutical and Bristol-Myers Squibb, and a research grant from Chiome Bioscience. H.I. received honoraria from Ono Pharmaceutical. K.N. received honoraria from Pfizer, Fujimoto Pharmaceutical, Senju Pharmaceutical, and Toray. H.S. received honoraria from Ono Pharmaceutical and Bristol-Myers Squibb, and research grants from Ono Pharmaceutical and Takeda Pharmaceutical. N.T. received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, and Taiho Pharmaceutical. T.K. received honoraria from Ono Pharmaceutical and Bristol-Myers Squibb. N.O. received honoraria from Taiho Pharmaceutical, Eisai, Bayer, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, and Nihon Servier. Y.N. received honoraria from Eli Lilly, Daiichi Sankyo, Taiho, Ono Pharmaceutical, and Bristol-Myers Squibb. Y.Y. received honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Taiho, Sanofi, Yakult, Nihon Servier, Lilly, Asahi Kasei Parma. K.A. received grants from Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Daiichi Sankyo, and Chiome Bioscience. K.M. received honoraria from Amgen, AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Daiichi Sankyo, Taiho, and Bristol-Myers Squibb. N.B. received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Eli Lilly, and Daiichi Sankyo. Other authors have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1125"}}